Status:
COMPLETED
Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Human Genome Research Institute (NHGRI)
University of Michigan
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is intended to examine the impact of receiving a genetic risk assessment for Alzheimer's disease (AD) among individuals with Mild Cognitive Impairment (MCI).
Detailed Description
Alzheimer's disease is a common condition affecting memory and thinking. Genes can sometimes be used to provide risk estimates for the eventual development of certain common diseases. Apolipoprotein E...
Eligibility Criteria
Inclusion
- Individuals (55-90 years old) with Mild Cognitive Impairment (amnestic-MCI as defined by the Petersen criteria)
- Individuals who have a close friend, relative or spouse (18+) willing to be a study partner. Study partners attend each study visit with the participant and also complete surveys and interviews.
Exclusion
- Individuals with current, untreated anxiety or depression
- Individuals who do not meet the criteria for amnestic-MCI
- Individuals who have the diagnosis of dementia or Alzheimer's disease
- Individuals not fluent in English
- Individuals who do not have a study partner
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT01434667
Start Date
January 1 2010
End Date
July 1 2014
Last Update
October 23 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Howard University
Washington D.C., District of Columbia, United States, 20060
2
University of Michigan
Ann Arbor, Michigan, United States, 48109
3
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104